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Discerning lymphatics from blood vessels using lineage-specific markers has
advanced our understanding of tumor lymphangiogenesis. Many studies have
demonstrated that the newly formed lymphatics are the result of a dynamic and
complex interplay between lymphatic endothelium, tumor cells, secreted growth
factors, and inhibitors in the tumor microenvironment. Results provide evidence
that lymphatics play an active role in cancer metastasis rather than once thought
to be passively invaded by infiltrating tumor cells. The latest discovery of Bracher
et al. (2012) further supports a dynamic role for lymphatics-mediated melanoma
metastasis to sentinel lymph node prompted by tumor-derived epidermal growth
factor.
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The cutaneous lymphatic vasculature
consists of a network of thin-walled
capillaries draining protein-rich lymph
from extracellular dermal and subcuta-
neous space within skin. A single-cell
layer of overlapping endothelial cells
lines the lymphatic capillaries, which
lack a continuous basement membrane,
in contrast to blood vessels. Over the
last decade, significant progress has
been made in our understanding of the
lymphatic system, with reagents that
discriminate lymphatics from blood ves-
sels, and using lymphatic-specific mar-
kers in human and mouse tissues
(Banerji et al., 1999; Schacht et al.,
2005). Discerning lymphatics from
blood vessels have, in turn, led to an
emerging complex view of molecular
regulation of lymphangiogenesis through
the formation of new lymphatics by a
dynamic process that includes prolifera-
tion, budding, and migration of
lymphatic endothelial cells (LECs). It is
a multifaceted signaling system involving
interaction among several growth factors,
inhibitors, and receptors (Alitalo and
Detmar, 2012). Although under normal
physiological conditions lymphangio-
genesis is largely absent in most adult
tissues, it can be induced by pathological
conditions such as inflammation, wound
healing, and cancer.
Some malignancies, including mela-
noma and breast cancer, have a propen-
sity for early microscopic dissemination
to sentinel lymph nodes (SLNs). Several
investigators have demonstrated inde-
pendently that nodal metastasis is asso-
ciated with lymphangiogenesis in
human melanoma (Dadras et al., 2003;
Shields et al., 2004; Dadras et al., 2005;
Massi et al., 2006; Shayan et al., 2012)
and in mouse xenograft models (Harrell
et al., 2007; Bracher et al., 2012).
Importantly, lymphatic invasion (LI),
defined as the presence of tumor cells
within intraluminal lymphatic spaces,
may represent an early step whereby
melanoma cells gain entry into the
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lymphatics by interacting with newly
formed vessels in the dermis (Figure 1).
In fact, LI was associated strongly with
melanoma metastasis to SLNs in a
cohort of 94 patients (Doeden et al.,
2009), and it was associated with sig-
nificantly poorer survival in a cohort of
251 patients (Xu et al., 2012).
Foci of LI in melanoma tissue sections
have exhibited an intact layer of lym-
phatic endothelium (Doeden et al.,
2009; Figure 1b), suggesting that lym-
phatics are not passive bystanders
invaded by cancer cells but rather active
participants in the metastatic process.
Therefore, the active involvement of
lymphatics does not support the earlier
concept that melanomas (in vertical
growth phase) have more invasive
access to the deep dermal venous/lym-
phatic plexuses. This new concept is
evidenced by tumor lymphangiogenesis
and LI as follows: (1) serving as inde-
pendent prognostic factors, i.e., inde-
pendent of tumor depth (Breslow’s
depth), and (2) being influenced by
tumor- or macrophage-derived factors.
Thus, tumor lymphangiogenesis is now
thought to represent a dynamic and
complex interplay between the lympha-
tic endothelium, tumor cells, secreted
growth factors, and inhibitors in the
tumor microenvironment. The latest dis-
covery of Bracher et al. (2012) supports




The authors elucidated a mechanism
by which a tumor-derived epidermal
growth factor (EGF) regulates lymphan-
giogenesis-mediated melanoma meta-
stasis to SLNs (Bracher et al., 2012). It
had been shown previously that collagen
and calcium-binding EGF domain-1 are
potent inducers of embryonic lymphan-
giogenesis in zebra fish (Hogan et al.,
2009), and that EGF is an inducer of
vascular endothelial growth factor-C
(VEGF-C) and other lymphangiogenic
factors. However, the direct role of
EGF in tumor lymphangiogenesis had
not been demonstrated. The authors
used a lentiviral microRNA expression
vector to interfere stably with endo-
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genously high levels of EGF mRNA in
the M24 melanoma cell line. Then, in a
series of experiments, they demonstrated
the biological effects of chronically
lowered EGF levels on an aggressive
cancer phenotype both in vitro and
in vivo. They observed the following:
(1) retarded migration rates in an
artificial wounding assay, (2) decreased
microscopic and macroscopic meta-
stases to SLNs in melanoma-bearing
SCID mice, but without influences on
tumor growth rates, (3) reduced tumor
lymphangiogenesis in xenografts in the
absence of effects on angiogenesis, and
(4) lowered VEGF-C expression mRNA
levels in the xenografts.
Interestingly, adding EGF directly to
immortalized LECs, but not to umbilical
vein endothelial cells, induced sprouting
in vitro; this response was abrogated by
adding EGF-neutralizing antibodies,
showing that EGF has an important role
in the migration of LECs. Thus, the results
demonstrated that EGF has an unex-
pected role in melanoma lymphangio-
genesis and metastasis to SLNs in SCID
mice. Moving forward, the investigators
conducted additional experiments to
examine the clinical significance of these
findings. They showed that EGF mRNA
levels correlated with the levels of
VEGF-C and Prox-1 by quantitative
reverse transcriptase–PCR; EGF protein
levels correlated well with that of
VEGF-C by immunohistochemistry in
archival melanoma specimens, indirectly
implying correlation with tumor lym-
phangiogenesis. However, no direct
measurement of tumor lymphangiogen-
esis, based on lymphatic-specific markers
in melanoma sections or its correlation to
EGF levels, was reported. The EGF serum
levels were significantly higher in 18
patients with metastatic melanoma to
SLNs compared with 42 individuals
who were free of the disease. Impor-
tantly, EGF did not correlate with Bre-
slow’s depth, consistent with the
previous findings that tumor lymphangio-
genesis or LI need not be dependent on
invasive melanomas to serve as a prog-
nostic marker.
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luminal side (arrowhead, b). Original magnification: a,  100; b,  400.
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